The FDA has approved brentuximab vedotin (Adcetris) for the treatment of primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides in patients who have received prior systemic therapy.
Achievement of event-free survival at 24 months is highly predictive of overall survival in patients with peripheral T-cell lymphomas, according to a new study.
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.
There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.
An 80-year-old man presented with a disabling pruritic rash characterized by disseminated and coalescing plaques on the trunk and proximal extremities and covering 40% of his total body surface area, without peripheral lymphadenopathy.
In this interview we discuss the different types of T-cell lymphomas and how supportive care is used in the management of these malignancies.
Patients with adult T-cell leukemia/lymphoma treated with mogamulizumab prior to undergoing allo-HSCT were at significantly greater risk for graft-vs-host disease–related mortality.
The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.
Receipt of EBRT for CTCL varies by sociodemographic factors and the centers where patients receive their care. Among those receiving EBRT, there are variations in dose, and median survival may vary by race. Further research is needed to assess differences in receipt, outcomes, and dose.
The injectable drug APO866, designed to induce apoptosis, did not have efficacy against cutaneous T-cell lymphoma, according to the results of small study.